Asthma and COPD drugs market to hit $55.67 billion by 2030

By AI, Created 11:07 AM UTC, May 20, 2026, /AGP/ – The global market for asthma and COPD medications is projected to grow from $35.66 billion in 2025 to $39.07 billion in 2026, then reach $55.67 billion by 2030. The growth outlook is tied to smoking, pollution, aging populations and a shift toward biologics, home care and combination inhalers.

Why it matters: - Asthma and COPD drugs treat chronic breathing conditions that affect airway function and day-to-day quality of life. - Rising demand for these medicines points to growing pressure on health systems as smoking, air pollution and aging populations increase respiratory illness burdens. - The market’s expansion also signals more use of inhalers, nebulizers and biologic therapies for long-term disease management.

What happened: - The Business Research Company said the asthma and COPD drugs market reached $35.66 billion in 2025 and is projected to rise to $39.07 billion in 2026. - The report puts the market on a path to $55.67 billion by 2030. - The report covers market trends across Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - Download the sample report. - View the full report.

The details: - The market posted 9.6% CAGR growth in the historical period, driven by higher smoking rates, worsening urban air pollution, improvements in hospital respiratory care, broader inhaler adoption and more asthma diagnoses. - The forecast period calls for 9.3% CAGR growth through 2030. - The report ties that growth to biologic drugs, an aging global population, deteriorating air quality, personalized respiratory treatments and home-based respiratory care. - Key trends include more combination inhaler therapies, stronger demand for long-acting bronchodilators, growth in biologics for severe asthma, a shift toward home care management and rising use of generic inhalation medicines. - Asthma and COPD drugs reduce airway inflammation, relax airway muscles and improve airflow to the lungs. - Inhalers and nebulizers are the main delivery methods.

Between the lines: - Smoking remains one of the clearest demand drivers for respiratory drugs because it directly worsens lung function and raises the risk of chronic respiratory disease. - An ERS study cited in the release found smoking rates among young people rose from 22.5% in 2022 to 40.1% in 2024, underscoring how early-life tobacco use can expand future treatment needs. - North America held the largest market share in 2025, reflecting its healthcare infrastructure and awareness levels. - Asia-Pacific is expected to be the fastest-growing region, helped by urbanization, pollution, wider healthcare access and a growing elderly population.

What’s next: - Market growth is expected to continue as biologics, personalized treatments and home-based care gain traction. - Demand should also rise for combination inhalers, long-acting bronchodilators and generic inhalation medicines. - The report’s regional outlook suggests the next phase of growth may come more from Asia-Pacific than from the largest current market in North America.

The bottom line: - Asthma and COPD drugs are moving from a $35.66 billion market in 2025 to a projected $55.67 billion by 2030, with smoking, pollution and aging populations keeping respiratory treatment demand elevated.